Protective efficacy was a low 31.2% and short-lived,15 and ADCC/Fc effector functional antibodies in the absence of an IgA response correlated with protection,15–17 whereas neutralizing antibody and cytotoxic T lymphocyte (CTL) responses were comparatively weak.18 In contrast to the unsuccessful VAX003 trial, the RV144 vaccine generated non-neutralizing Abs with multiple FcγR functions, with higher IgG1 and IgG3 levels.19 These studies support a critical role for IgG FcγR binding activity in protection from HIV infection. The gene discussed is FCGR2A; the disease is HIV infectious disease.